Neo Ivy Capital Management Neurocrine Biosciences Inc Transaction History

Neo Ivy Capital Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 24, 2023	BUY	$106.72 - $127.06 $267,013 - $317,904	2,502 Added 1390.0%	2,682 $320,000
Q3 2022 Nov 15, 2022	BUY	$92.03 - $107.81 $16,565 - $19,405	180 New	180 $19,000
Q2 2022 Aug 16, 2022	SELL	$75.79 - $100.07 $167,950 - $221,755	-2,216 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $16,808 - $21,995	232 Added 11.69%	2,216 $208,000
Q4 2021 Feb 15, 2022	BUY	$79.65 - $106.22 $158,025 - $210,740	1,984 New	1,984 $168,000
Q3 2021 Nov 16, 2021	SELL	$86.18 - $99.03 $12,323 - $14,161	-143 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $12,788 - $14,624	143 New	143 $14,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $337,558 - $420,753	-3,884 Closed	0 $0
Q3 2020 Nov 17, 2020	BUY	$96.16 - $135.15 $239,149 - $336,118	2,487 Added 178.02%	3,884 $373,000
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $161,186 - $244,128	-2,146 Reduced 60.57%	1,397 $121,000
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $307,532 - $420,093	3,543 New	3,543 $381,000
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $450,445 - $594,853	-6,499 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $444,011 - $808,215	6,499 New	6,499 $464,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.